These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10620310)

  • 21. Intermediate and long-acting insulin preparations without protamine sulphate are complement activators in vitro.
    Duchateau J; Schreyen H; Dorchy H
    Diabete Metab; 1992; 18(4):272-6. PubMed ID: 1459314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Postprandial glycemic control using insulin aspart with NPH in inadequately controlled diabetics].
    Gao Y; Pan CY; Zou DJ; Xu ZR; Liu XM; Guo XH
    Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(28):1960-3. PubMed ID: 19950569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tapping-mode atomic force microscopy produces faithful high-resolution images of protein surfaces.
    Möller C; Allen M; Elings V; Engel A; Müller DJ
    Biophys J; 1999 Aug; 77(2):1150-8. PubMed ID: 10423460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigation of mechanical properties of insulin crystals by atomic force microscopy.
    Guo S; Akhremitchev BB
    Langmuir; 2008 Feb; 24(3):880-7. PubMed ID: 18163652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA condensation by protamine and arginine-rich peptides: analysis of toroid stability using single DNA molecules.
    Balhorn R; Brewer L; Corzett M
    Mol Reprod Dev; 2000 Jun; 56(2 Suppl):230-4. PubMed ID: 10824973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AFM analysis of DNA-protamine complexes bound to mica.
    Allen MJ; Bradbury EM; Balhorn R
    Nucleic Acids Res; 1997 Jun; 25(11):2221-6. PubMed ID: 9153324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Update on new insulins].
    Tapia Ceballos L
    An Pediatr (Barc); 2009 Jan; 70(1):65-71. PubMed ID: 19174123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens.
    Jehle PM; Micheler C; Jehle DR; Breitig D; Boehm BO
    Lancet; 1999 Nov; 354(9190):1604-7. PubMed ID: 10560676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloidogenic self-assembly of insulin aggregates probed by high resolution atomic force microscopy.
    Jansen R; Dzwolak W; Winter R
    Biophys J; 2005 Feb; 88(2):1344-53. PubMed ID: 15574704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of neutral protamine lispro (NPL) insulin in a patient affected by acute pancreatitis under parenteral nutrition.
    Fatati G; Mirri E; Papi M; Coaccioli S
    Clin Ter; 2011; 162(3):231-4. PubMed ID: 21717048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
    Gupta V; Baabbad R; Hammerby E; Nikolajsen A; Shafie AA
    J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preparation of a microcrystalline suspension formulation of Lys(B28)Pro(B29)-human insulin with ultralente properties.
    Richards JP; Stickelmeyer MP; Frank BH; Pye S; Barbeau M; Radziuk J; Smith GD; DeFelippis MR
    J Pharm Sci; 1999 Sep; 88(9):861-7. PubMed ID: 10479347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
    Arutchelvam V; Heise T; Dellweg S; Elbroend B; Minns I; Home PD
    Diabet Med; 2009 Oct; 26(10):1027-32. PubMed ID: 19900235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
    Levin P
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surface characterization of aspirin crystal planes by dynamic chemical force microscopy.
    Danesh A; Davies MC; Hinder SJ; Roberts CJ; Tendler SJ; Williams PM; Wilkins MJ
    Anal Chem; 2000 Aug; 72(15):3419-22. PubMed ID: 10952521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzymatic degradation processes of lamellar crystals in thin films for poly[(R)-3-hydroxybutyric acid] and its copolymers revealed by real-time atomic force microscopy.
    Numata K; Hirota T; Kikkawa Y; Tsuge T; Iwata T; Abe H; Doi Y
    Biomacromolecules; 2004; 5(6):2186-94. PubMed ID: 15530032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn therapy for newly diagnosed type 1 diabetes.
    Al Shamsi AM
    Pediatrics; 2008 Sep; 122(3):675-6; author reply 676. PubMed ID: 18762540
    [No Abstract]   [Full Text] [Related]  

  • 39. Protamine loops DNA in multiple steps.
    Ukogu OA; Smith AD; Devenica LM; Bediako H; McMillan RB; Ma Y; Balaji A; Schwab RD; Anwar S; Dasgupta M; Carter AR
    Nucleic Acids Res; 2020 Jun; 48(11):6108-6119. PubMed ID: 32392345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low molecular weight protamine (LMWP): a nontoxic protamine substitute and an effective cell-penetrating peptide.
    He H; Ye J; Liu E; Liang Q; Liu Q; Yang VC
    J Control Release; 2014 Nov; 193():63-73. PubMed ID: 24943246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.